ECO 2024 — Dr Donna H Ryan (Pennington Biomedical Research Center, US) joins us to discuss the first sub-analysis of the landmark SELECT trial (NCT03574597, Novo Nordisk).

In this study, investigators looked at long-term weight loss with semaglutide 2.4 mg compared to a placebo among 17,604 participants. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss compared to placebo. Weight loss was sustained over 4 years.

Questions

1. What are the unmet needs of patients with overweight and obesity and CV disease in 2024?
2. What are your key findings?
3. How should these findings be put into clinical practice?
4. What are the challenges and opportunities in this treatment area, and what are the next steps?

Support: This is independent content produced by Radcliffe Cardiology.

Videographer: Oliver Miles 

Interviewer: Jordan Rance 

Editor: Mirjam Boros